<DOC>
	<DOC>NCT01323062</DOC>
	<brief_summary>This is a non-randomized, open-label Phase 1b trial to establish the safety and recommended phase 2 dose (RP2D) of bavituximab in combination with pemetrexed and carboplatin in subjects with previously untreated stage IV non-squamous non-small cell lung cancer (NSCLC).</brief_summary>
	<brief_title>Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects</brief_title>
	<detailed_description>Subjects with measurable disease will be assessed for response after every 2 cycles of therapy using RECIST 1.1 criteria. In addition, progression free survival (PFS), overall survival (OS) and exploratory biomarkers, imaging, and thrombotic risk parameters will be evaluated.</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Greater than or equal to 18 Histologically or cytologically confirmed stage IV nonsquamous NSCLC not previously treated with systemic chemotherapy Evaluable disease by clinical or radiographic parameters No history or concomitant malignancy Adequate organ and marrow function Female subjects with negative urine or serum pregnancy ECOG must be 0 or 1 Squamous cell, small cell, or mixed histology Known history of bleeding diathesis or coagulopathy Cavitary tumors or tumors invading or abutting large blood vessels Any history of thromboembolic events Ongoing therapy with oral or parenteral anticoagulants Major surgery within 4 weeks of Day 1 of treatment Uncontrolled intercurrent disease (diabetes, hypertension, thyroid disease) any history of significant vascular disease Congestive heart failure History of any condition requiring antiplatelet therapy Serious non healing wound Known chronic infection with human immunodeficiency virus (HIV) or viral hepatitis Unable or unwilling to discontinue use of prohibited medications Ddimers &gt;2 x ULN as measured on 2 separate occasions at least 1 day apart</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>chemotherapy naive</keyword>
	<keyword>stage IV non squamous non small cell lung cancer</keyword>
	<keyword>Phase 1b</keyword>
	<keyword>Bavituximab</keyword>
	<keyword>Chimeric 3G4</keyword>
	<keyword>U of North Carolina at Chapel Hill</keyword>
</DOC>